Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Topotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 19/20 | 0.95 |
| ▸ | MEN1 | O00255 | 5/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.95 |
| ▸ | CASP1 | P29466 | 3/20 | 0.95 |
| ▸ | CASP7 | P55210 | 3/20 | 0.95 |
| ▸ | HBB | P68871 | 3/20 | 0.95 |
| ▸ | MAPT | P10636 | 3/20 | 0.95 |
| ▸ | USP2 | O75604 | 2/20 | 0.95 |
| ▸ | LMNA | P02545 | 2/20 | 0.95 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.95 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.95 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.95 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.95 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.95 |
| ▸ | TOP2A | P11388 | 1/20 | 0.95 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.95 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Topotecan SCHEMBL27625552 | 0.99 | TOP1 (0.95) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL29350221 | 0.98 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL5531617 | 0.98 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL9971346 | 0.98 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL29726458 | 0.98 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL14577671 | 0.98 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL3836 | 0.98 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL3927536 | 0.98 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL31517322 | 0.98 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL30712226 | 0.98 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547785-B2 | Process for preparing topotecan | DR. REDDY'S LABORATORIES LIMITED (IN) | 2009-06-16 | — | — | US | claimed |
| US-20070149783-A1 | PROCESS FOR PREPARING TOPOTECAN | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-06-28 | — | — | US | claimed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | EDISON ONCOLOGY (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4297746-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED COMPOUNDS AND THERAPIES FOR THE TREATMENT OF DISEASES | Edison Oncology (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| EP-3592393-B1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| EP-2459220-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | Ascendis Pharma A/S (DK) | 2012-06-06 | — | — | EP | disclosed |
| CN-102439071-A | Gaba-linked anthracycline-lipid conjugates | LUITPOLD PHARM INC | 2012-05-02 | — | — | CN | disclosed |
| WO-2011089214-A1 | CARRIER-LINKED CARBAMATE PRODRUG LINKERS | ASCENDIS PHARMA AS (DK) | 2011-07-28 | — | — | WO | disclosed |
| CN-101555250-B | Preparation method of topotecan hydrochloride | CHONGQING TAIHAO PHARMACEUTICAL CO LTD | 2011-05-18 | — | — | CN | disclosed |
| WO-2011012715-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | disclosed |
| CN-101555250-A | Preparation method of topotecan hydrochloride | CHONGQING TAIHAO PHARMACEUTICA (CN) | 2009-10-14 | — | — | CN | disclosed |
| US-7547785-B2 | Process for preparing topotecan | DR. REDDY'S LABORATORIES LIMITED (IN) | 2009-06-16 | — | — | US | disclosed |
| US-20070149783-A1 | PROCESS FOR PREPARING TOPOTECAN | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | TOP1 2925/4885MEN1 4821/4885KMT2A 3136/4885 |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | TOP2A, TOP2B, TOP1 | TOP1 3/4885MEN1 601/4885KMT2A 1727/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | TOP1 2925/4885MEN1 4821/4885KMT2A 3136/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | TOP1 775/4885MEN1 2694/4885KMT2A 4144/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | TOP1 2925/4885MEN1 4821/4885KMT2A 3136/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | TOP1 775/4885MEN1 2694/4885KMT2A 4144/4885 |
| US-20070149783-A1 | PROCESS FOR PREPARING TOPOTECAN | TOP2A, TOP1, TYMP | TOP1 2/4885MEN1 963/4885KMT2A 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.